DrugPatentWatch Database Preview
LENVIMA Drug Profile
Which patents cover Lenvima, and when can generic versions of Lenvima launch?
Lenvima is a drug marketed by Eisai Inc and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in LENVIMA is lenvatinib mesylate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the lenvatinib mesylate profile page.
Summary for LENVIMA
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 65 |
| Clinical Trials: | 9 |
| Patent Applications: | 12 |
| Drug Prices: | Drug price information for LENVIMA |
| DailyMed Link: | LENVIMA at DailyMed |
Generic Entry Opportunity Date for LENVIMA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for LENVIMA
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Receptor Tyrosine Kinase Inhibitors |
Synonyms for LENVIMA
| 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide |
| 4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide |
| 4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide |
| 4-[3-chloranyl-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide |
| 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide |
| 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide |
| 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide |
| 4-[3-chloro-4-[[(cyclopropylamino)-oxomethyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide |
| 4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide |
| 417716-92-8 |
| 4CA-0485 |
| 716C928 |
| A1-04306 |
| A825653 |
| ABP000863 |
| AC-25047 |
| AK175809 |
| AKOS025401742 |
| AN-6642 |
| AOB87766 |
| AS-16203 |
| BC252209 |
| BCP9000633 |
| BCPP000247 |
| BDBM50331094 |
| CHEBI:85994 |
| CHEMBL1289601 |
| CS-0109 |
| CTK1D4875 |
| D09919 |
| D0R0FO |
| DB-070219 |
| DB09078 |
| DTXSID50194605 |
| E 7080 |
| E-7080 |
| E-7080, E7080 |
| E7080 |
| E7080 (Lenvatinib) |
| E7080, E 7080 |
| E7080/E-7080 |
| EE083865G2 |
| ER-203492-00 |
| EX-A249 |
| FT-0700727 |
| GTPL7426 |
| HE068062 |
| HE342379 |
| HMS3244A07 |
| HMS3244A08 |
| HMS3244B07 |
| HMS3654A14 |
| HY-10981 |
| J-513372 |
| KB-78118 |
| Kisplyx |
| KS-00000638 |
| Lenvatinib |
| Lenvatinib (E7080) |
| Lenvatinib (USAN/INN) |
| Lenvatinib [USAN:INN] |
| Lenvatinib mesilate |
| Lenvatinib; E7080 |
| LenvatinibE7080) |
| LEV |
| MFCD16038644 |
| MLS006011239 |
| MolPort-009-679-469 |
| NCGC00263198-01 |
| QCR-115 |
| RS0099 |
| s1164 |
| SC-87813 |
| SCHEMBL864638 |
| SMR004702999 |
| SYN1038 |
| UNII-EE083865G2 |
| WOSKHXYHFSIKNG-UHFFFAOYSA-N |
| ZINC3816292 |
US Patents and Regulatory Information for LENVIMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for LENVIMA
Supplementary Protection Certificates for LENVIMA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015039,C1698623 | Lithuania | ➤ Sign Up | PRODUCT NAME: LENVATINIBAS; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528 |
| 858 | Luxembourg | ➤ Sign Up | PRODUCT NAME: LENVATINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES OU UN HYDRATE DE CELUI-CI |
| /2015 | Austria | ➤ Sign Up | PRODUCT NAME: LENVATINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON ODER EIN HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/15/1002/001-002 (MITTEILUNG) 20150601 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
